Overview

DPP4 Inhibitor on Glycemic Variability

Status:
Completed

Trial end date:
2019-08-31

Target enrollment:

Participant gender:

Summary

The investigators conducted a prospective study in patients with T2DM on twice daily MHI with or without metformin therapy. Blinded continuous glucose monitoring was performed at baseline and following 6 weeks of Vildagliptin therapy.

Phase:

Phase 4

Details

Lead Sponsor:

University Malaysia Sarawak

Collaborator:

Sarawak General Hospital

Treatments:

Vildagliptin